Lamassu Recently Earned Prestigious NIH Grant and Won FDA Approval to Trial Potentially Transformative Treatment for Metastatic Cancers
(CLEVELAND, OH) – One of the pharmaceutical industry’s most leading-edge companies, Lamassu Biotech is proud to announce the establishment of new corporate offices in Cleveland, Ohio, marking a significant milestone for the firm and its continuing efforts to bring innovative treatments to patients around the world.
Lamassu has been making strides toward new cancer therapies that could transform oncology practices and the treatment of cancers that presently do not respond to treatment. The company’s strategic partners include both the Mayo Clinic and Cleveland Clinic, as well as McGill University and the National Cancer Center, among others.
City of Cleveland Mayor Justin M. Bibb stated, “Cleveland continues to grow as a hub for innovation and technology. We are thrilled to welcome Lamassu Biotech as they move their corporate headquarters to our city. Their decision not only enhances our community but also signifies a substantial investment in our future, solidifying Cleveland’s position as a leader in healthcare innovation on a national level.”
In collaboration with the Cleveland Clinic and NIH, Lamassu recently secured a coveted grant for the development of their genetically targeted cancer therapy. Recognized with the highest award from the NIH, this therapy underscores its potential to transform oncology practices, a recognition reserved for only a select few companies.
In March, Lamassu received FDA approval to initiate a Phase 1/2a clinical trial for its groundbreaking cancer treatment protocol. The trials will begin in conjunction with the Cleveland Clinic in the coming months. Lamassu’s novel therapy, developed in partnership with a major European pharmaceutical company, targets hard-to-treat cancers with precision. This approach holds promise for patients with limited treatment options, offering an alternative to invasive and often ineffective therapies.
“We are honored to now be a part of the business community here in Cleveland as we continue on this pioneering journey in cancer treatment,” said Dr. Gabi Hanna, CEO of Lamassu Biotech. “The support and collaboration from the Cleveland Clinic, NIH, and now the City of Cleveland, will help propel our mission forward. Together, we are committed to bringing hope and healing to patients facing challenging cancer diagnoses the world-over.”
ABOUT LAMASSU BIOTECH
Accelerating treatment means saving more lives. At Lamassu, our team of dedicated physicians, engineers, and translational scientists, are driven by a passion to treat patients like family. Our goal is to speed the innovation process by bringing transformational treatments from concept to bedside faster than other companies. Lamassu’s patient-centric approach to research focuses on making advancements that address unmet needs with novel and targeted strategies, ensuring greater efficiency and shorter approval timeframes. With decades of experience developing leading medical treatments, we believe that it is not only the transformative power of science, but also hope that leads to healing. Learn more at LamassuBioTech.com.